Life Science Nation Newsletter | November 15, 2018 | Issue 292

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
RESI San Francisco 2019
  Life Science Investor Mandates  (Nov. 8 - Nov. 14 )
with Over $1B+ AUM Invests in Therapeutics, Devices, Diagnostics, Digital Health, and Drug Discovery & Research Tools
Invests Up to $12M Over Life of Investment, with Strongest Interests in Therapeutics and Device Companies
Invests Up to $7M in Early-Stage Medical Devices & Diagnostics in Markets of Unmet Medical Need, Ideally of at Least $10B
Open to Investing Across All Life Scienc-Related Sectors, with Focus in South California & Southwestern USA
LSN Services
LSN Videos
LSN Media Partners
By Claire Jeong, Senior Research Analyst, LSN

After finishing off another successful RESI event in New York City just last week, the LSN team is excitedly preparing for RESI San Francisco during JPM week on Tuesday, January 8th, 2019, our largest event of the year! We are now accepting applications for the RESI SF 2019 Innovation Challenge through our online portal, and companies can also submit a completed PDF application and supplementary materials to Our deadline is Friday, December 7th, 2018.

As usual, we will select 30 finalists from a pool of over 100 applicants across the globe and provide these finalists with the opportunity to present a posterboard showcasing their technologies at our exhibition hall for the entire day. The Innovation Challenge is open to early-stage companies in all sectors, from therapeutics, medical devices, diagnostics, and digital health.

Since RESI Boston in September 2018, we have been working with many regional tech hubs to bring the earliest stage technologies in front of our global network of investors. We will be selecting several companies to participate in the West Coast Innovators' Pitch Challenge, to pitch in front of a panel of investor judges...

By Lucy Parkinson, VP of Investor Research, LSN

At LSN, we're looking forward to a RESI San Francisco packed with meetings, content and new connections. Over a thousand attendees will join us for the event, and hundreds of investors are already registered to attend. In addition to the networking potential of RESI San Francisco, LSN has also created an agenda full of investor panels related to key technologies and sources of investment in the early stage life science arena. These panels aim to inform entrepreneurs on who's out there writing checks, and how to get on their radar.

RESI San Francisco will feature an Asia Track in the afternoon, including a new panel on Asia Corporates & Strategics, and our first ever devoted panel on Taiwan Investors, led by BioMed Taiwan. The event also includes RESI's first ever panel devoted to Investing in Cell & Gene Therapy, a West Coast Innovator's Pitch Challenge, and the return of RESI's popular sessions on Mental & Behavioural Health, Corporate Venture Capital, and Personalized Medicine. If you'd like to join us for this full day of content, register now!

By Karen Deyo, Investor Research Analyst, LSN

The Digital Health sector has been rapidly expanding, with applications ranging from consumer-facing technologies to physician tools for care coordination to AI-based diagnostics platforms. The nature of this sector, with the much shorter time-to-commercialization as well as the ease in entering the market has led to a great deal of investment in this space. However, this leads to some big differences in the strategies employed by investors, as well as unique challenges faced by fundraising CEOs in this space. In addition, companies and investors alike must take into account the shifting regulatory environment as the FDA grapples with a strategy to evaluate Digital Health technologies, either as standalone products or as part of combination devices.

At our upcoming RESI conference in San Francisco on January 8th, we have five investors who focus on Digital Health who are willing to share their expertise about what's hot, what not to do and how to face the challenges and avoid the pitfalls that are common in this sector. Make sure to make your way to the panel, taking place from 10:00-10:50 am!

The panelists speaking on the Digital Health panel are:
  • Dennis Depenbusch, Director, New Ventures Initiative, BCBSKS New Ventures Initiative
  • Brenda Irwin, Managing Partner & Co-Founder, Relentless Pursuit Partners
  • Dominik Mayer, Principal, AO Invest
  • Skip Fleshman, Partner, Asset Management Ventures
  • Debbie Lin, Executive Director - Digital Health, Boehringer Ingelheim Venture Fund

Created & Produced by